EBS Financial Facts

Net income (loss) attributable to Emergent BioSolutions Inc.: 21.83M
Research and development: 44.21M
See Full Income Statement

Deferred revenue, net of current portion: 5.82M
Additional paid-in capital: 264.88M
See Full Balance Sheet

Emergent BioSolutions, Inc. (EBS) Earnings

  |   Expand Research on EBS
Next EPS Date 2/10/15 *Est. EPS Growth Rate +59.5% *Last Qtr.
Average EPS % Beat Rate -76.7% Revenue Growth Rate +46.7% *Last Qtr.
Average % Move 1-Wk after EPS -0.5% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/6/14 Q414 $0.67$0.52 +$0.15$138M$126.9M N/A Details
3/8/12 Q411 $0.78$0.72 +$0.06$107.95M$109.32M = Details
8/7/14 Q214 $0.13$0.32 -$0.19$110.3M$109.25M Details
3/10/11 Q410 $0.78$0.67 +$0.11$103.2M$102.03M = Details
3/7/13 Q412 $0.44$0.45 -$0.01$94.6M$95.09M = Details
3/6/14 Q413 $0.42$0.36 +$0.06$94.1M$93.83M Details
8/4/11 Q211 $0.40$0.34 +$0.06$88.1M$84.2M = Details
11/7/13 Q313 $0.37$0.21 +$0.16$89.1M$79.13M = Details